“The International Generic and Biosimilar medicines Association (IGBA) invites generic and biosimilar medicines manufacturers to actively engage and commit to contributing to the global manufacturing capacity once an existing or newly-discovered therapeutic is proven to be effective against COVID-19.
IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, today pays tribute to Bill Haddadi, who passed away last week. He was a pioneer in the development of generic medicine policy in the U.S.A. and a remarkable advocate for access to medicines worldwide.
IGBA, the International Generic and Biosimilar medicines Association (IGBA), representing global manufacturers of generic and biosimilar medicines, today endorses the commitment and call to action by an initial group of global health actors, private sector partners and other stakeholders, to launch an unprecedented global and time-limited collaboration to accelerate the development, production and equitable global access to new COVID-19 essential health technologies.
- IGBA Contributes to Global Discussion on Tailored Clinical Biosimilar Development with New Peer-Reviewed Scientific Paper (10 April 2020)
- COVID-19: IGBA calls for urgent priority designation for medicines at custom controls and for cargo and freight (6 April 2020)
- COVID-19: IGBA urgent recommendations to keep medicine supply chains flowing (27 March 2020)
- COVID-19: Urgent call to governments - Air freight must reopen for critical medicines and supplies for their manufacture (23 March 2020)
